EKLF/CKLF/UKLF, Polyclonal Antibody

KLF1; EKLF; Krueppel-like factor 1; Erythroid krueppel-like transcription factor; EKLF; KLF5; BTEB2; CKLF; IKLF; Krueppel-like factor 5; Basic transcription element-binding protein 2; BTE-binding protein 2; Colon krueppel-like factor; GC-bo

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit

EKLF/CKLF/UKLF Polyclonal Antibody detects endogenous levels of EKLF/CKLF/UKLF protein.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

1 mg/ml (lot specific)

Store at -20 degree C/1 year

Small volumes of anti-EKLF/CKLF/UKLF antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Total protein Ab

Western Blot (WB), Immunofluorescence (IF), ELISA (EIA)

Western Blot: 1:500 - 1:2000
Immunofluorescence: 1:200 - 1:1000
ELISA: 1:20000
Not yet tested in other applications.

Western Blot analysis of VEC cells using EKLF/CKLF/UKLF Polyclonal Antibody

Western Blot analysis of VEC HY926 cells using EKLF/CKLF/UKLF Polyclonal Antibody

38,221 Da

Kruppel-like factor 1 (erythroid)

Krueppel-like factor 1

Krueppel-like factor 1

EKLF; EKLF  [Similar Products]

KLF1_HUMAN

This gene encodes a hematopoietic-specific transcription factor that induces high-level expression of ***** beta-globin and other erythroid genes. The zinc-finger protein binds to the DNA sequence CCACACCCT found in the beta hemoglobin promoter. Heterozygous loss-of-function mutations in this gene result in the dominant In(Lu) blood phenotype. [provided by RefSeq, Oct 2009]

KLF1: Transcription regulator of erythrocyte development that probably serves as a general switch factor during erythropoiesis. Is a dual regulator of fetal-to-***** globin switching. Binds to the CACCC box in the beta-globin gene promoter and acts as a preferential activator of this gene. Furthermore, it binds to the BCL11A promoter and activates expression of BCL11A, which in turn represses the HBG1 and HBG2 genes. This dual activity ensures that, in most *****s, fetal hemoglobin levels are low. Able to activate CD44 and AQP1 promoters. When sumoylated, acts as a transcriptional repressor by promoting interaction with CDH2/MI2beta and also represses megakaryocytic differentiation. Defects in KLF1 are the cause of congenital dyserythropoietic anemia type 4 (CDA4). It is a blood disorder characterized by ineffective erythropoiesis and hemolysis resulting in anemia. Circulating erythroblasts and erythroblasts in the bone marrow show various morphologic abnormalities. Affected individuals with CDA4 also have increased levels of fetal hemoglobin. Belongs to the krueppel C2H2-type zinc-finger protein family.

Protein type: Transcription factor; DNA-binding; C2H2-type zinc finger protein

Chromosomal Location of Human Ortholog: 19p13.2

Cellular Component: nuclear chromatin; nucleus

Molecular Function: metal ion binding; transcription factor activity

Biological Process: chromatin remodeling; erythrocyte maturation; transcription, DNA-dependent; in utero embryonic development; embryonic hemopoiesis; positive regulation of transcription, DNA-dependent; erythrocyte differentiation; liver development

Disease: Fetal Hemoglobin Quantitative Trait Locus 6; Anemia, Congenital Dyserythropoietic, Type Iv; Blood Group--lutheran Inhibitor

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.